Mylan (MYL) Receives FDA Approval for Generic Version of Takeda's Actoplus Met
- Top 10 News for 8/24 - 8/28: Markets Volatile on Continued China Worries; Revised Q2 GDP Outpaces; Facebook Hits User Activity Milestone
- Buffett's Berkshire Hathaway Discloses ~$4.5B Stake in Phillips 66 (PSX)
- Wall Street ends flat in quiet end to dramatic week
- Carl Icahn files 13D on Freeport-McMoran (FCX)
- Autodesk (ADSK) Tops Q2 EPS by 2c; Issues Light Q3 Outlook
Bloomberg reporting Mylan (NYSE: MYL) has won FDA approval for its generic version of Takeda's actoplus met.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Sees Two Issues that Could Limit Mylan (MYL) Upside Amid Move to Acquire Perrigo (PRGO)
- Mylan (MYL) Affirms Challenge to Two Copaxone Patents (TEVA)
- UPDATE: Momenta Phama (MNTA) Whipsawed; Teva (TEVA) Capaxone Patents Under Scrutiny Said to be for Long-Acting Version - Bloomberg
Create E-mail Alert Related CategoriesFDA, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!